Insider Selling: BeiGene, Ltd. (BGNE) Director Sells 35,000 Shares of Stock
BeiGene, Ltd. (NASDAQ:BGNE) Director Xiaodong Wang sold 35,000 shares of the business’s stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $44.95, for a total transaction of $1,573,250.00. Following the completion of the transaction, the director now owns 26,600 shares in the company, valued at approximately $1,195,670. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Xiaodong Wang also recently made the following trade(s):
- On Friday, June 2nd, Xiaodong Wang sold 5,539 shares of BeiGene stock. The stock was sold at an average price of $40.00, for a total transaction of $221,560.00.
- On Thursday, May 4th, Xiaodong Wang sold 14,461 shares of BeiGene stock. The stock was sold at an average price of $40.80, for a total transaction of $590,008.80.
- On Wednesday, April 5th, Xiaodong Wang sold 11,650 shares of BeiGene stock. The stock was sold at an average price of $36.83, for a total transaction of $429,069.50.
Shares of BeiGene, Ltd. (NASDAQ:BGNE) traded up 0.29% during midday trading on Friday, hitting $45.00. 60,890 shares of the stock were exchanged. The firm’s market cap is $1.79 billion. BeiGene, Ltd. has a 12-month low of $24.53 and a 12-month high of $46.00. The stock’s 50 day moving average is $40.06 and its 200 day moving average is $37.01.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: BeiGene, Ltd. (BGNE) Director Sells 35,000 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/30/insider-selling-beigene-ltd-bgne-director-sells-35000-shares-of-stock.html.
A number of hedge funds have recently modified their holdings of BGNE. State Street Corp increased its stake in shares of BeiGene by 6.0% in the fourth quarter. State Street Corp now owns 33,769 shares of the company’s stock worth $1,025,000 after buying an additional 1,917 shares during the period. FMR LLC increased its stake in shares of BeiGene by 18.1% in the fourth quarter. FMR LLC now owns 3,880,425 shares of the company’s stock worth $117,810,000 after buying an additional 593,896 shares during the period. Guggenheim Capital LLC bought a new stake in shares of BeiGene during the fourth quarter worth $670,000. Norges Bank bought a new stake in shares of BeiGene during the fourth quarter worth $607,000. Finally, Vident Investment Advisory LLC increased its stake in shares of BeiGene by 9.7% in the fourth quarter. Vident Investment Advisory LLC now owns 24,958 shares of the company’s stock worth $758,000 after buying an additional 2,207 shares during the period. 55.69% of the stock is owned by hedge funds and other institutional investors.
BGNE has been the topic of a number of recent analyst reports. Maxim Group set a $52.00 price objective on shares of BeiGene and gave the stock a “buy” rating in a report on Thursday, March 2nd. William Blair reiterated an “outperform” rating on shares of BeiGene in a report on Thursday, June 1st. Finally, Zacks Investment Research lowered shares of BeiGene from a “hold” rating to a “sell” rating in a report on Monday, March 27th.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.